Head-to-head preclinical treatment design prioritizes promising therapies for neurofibromatosis type 1 optic glioma clinical translation
This referential preclinical study design affords direct head-to-head comparisons of investigational therapies relative to SOC treatment using clinically meaningful outcomes (OPG growth and RNFL thickness). Using this strategy, lamotrigine emerged as the most promising therapy for limiting tumor progression and vision loss in <i>Nf1</i>-OPG mice, relevant to clinical translation for children with NF1-OPG.
Authors
- Jason Fangusaro (ORCID: https://orcid.org/0000-0003-3099-5259)
- Hareesh B. Nair
- A. Kirchner
- David H. Gutmann (ORCID: https://orcid.org/0000-0002-3127-5045)
- Shintaro Yamada (ORCID: https://orcid.org/0000-0002-3240-358X)
- Jit Chatterjee (ORCID: https://orcid.org/0000-0002-2444-9748)
- Talia Eligator
Institutions
- Texas Tech University (US)
- Emory University (US)
- Washington University in St. Louis (US)
- Children's Healthcare of Atlanta (US)
- Texas Tech University Health Sciences Center (US)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/noajnl/vdaf215
- Citations
- 1
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Georgia Clinical and Translational Science Alliance
- National Institutes of Health
- National Cancer Institute
- National Center for Research Resources